Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Neuroone Medical Technologies (NMTC) over the last 14 years, with Q4 2025 value amounting to -$3.2 million.

  • Neuroone Medical Technologies' Free Cash Flow fell 181896.61% to -$3.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$6.2 million, marking a year-over-year increase of 1252.29%. This contributed to the annual value of -$2.9 million for FY2025, which is 7377.83% up from last year.
  • Neuroone Medical Technologies' Free Cash Flow amounted to -$3.2 million in Q4 2025, which was down 181896.61% from -$1.5 million recorded in Q3 2025.
  • In the past 5 years, Neuroone Medical Technologies' Free Cash Flow ranged from a high of $951635.0 in Q3 2022 and a low of -$3.8 million during Q4 2023
  • Its 5-year average for Free Cash Flow is -$2.2 million, with a median of -$2.5 million in 2021.
  • In the last 5 years, Neuroone Medical Technologies' Free Cash Flow skyrocketed by 14609.71% in 2022 and then crashed by 181896.61% in 2025.
  • Quarter analysis of 5 years shows Neuroone Medical Technologies' Free Cash Flow stood at -$2.7 million in 2021, then dropped by 27.85% to -$3.5 million in 2022, then fell by 9.78% to -$3.8 million in 2023, then soared by 104.77% to $183633.0 in 2024, then tumbled by 1818.97% to -$3.2 million in 2025.
  • Its Free Cash Flow was -$3.2 million in Q4 2025, compared to -$1.5 million in Q3 2025 and -$1.5 million in Q2 2025.